Ashkenazi Jews carry higher rates of certain genetic diseases because their population went through severe bottlenecks, shrinking to very small numbers at key points in history, then expanding rapidly while remaining relatively isolated through centuries of marrying within the community. This combination of small founding populations, rapid growth, and endogamy concentrated certain gene variants that would otherwise be rare.
The Population Bottleneck Effect
The core explanation is a concept called the founder effect. When a large population shrinks dramatically, the survivors carry only a fraction of the original genetic diversity. Whatever rare mutations those survivors happen to carry become much more common in future generations, especially if the population grows quickly afterward and remains relatively closed to outsiders.
The Ashkenazi population experienced at least two major bottlenecks. The first occurred around 70 A.D., at the beginning of the Jewish Diaspora, when a population estimated at roughly one million was dramatically reduced. The second, and likely more impactful, occurred between roughly 1100 and 1400 A.D. Before the Crusades began in 1096, Jewish communities across Germany, France, and England numbered at least 100,000 people. The persecutions during the Crusades and the mortality from the Black Death collapsed that number. By 1500, the entire Ashkenazi population in eastern Europe is estimated to have been just 10,000 to 20,000 people.
What happened next matters just as much. From that tiny base, the population exploded: 200,000 by 1648, 750,000 by 1765, and six million by 1900. That rapid expansion meant the gene variants present in those 10,000 to 20,000 survivors were amplified across millions of descendants. Researchers have identified evidence of at least three distinct founder events stretching back over 100 generations.
Why Endogamy Matters
A bottleneck alone doesn’t guarantee elevated disease rates if the population subsequently mixes with surrounding groups. But Ashkenazi Jews maintained a high degree of endogamy, meaning marriage within the community, for centuries. This cultural and religious practice kept the gene pool relatively closed, preventing the dilution of disease-causing variants through intermarriage with neighboring populations. Genetic analysis shows that this relative isolation, combined with genetic drift (the random fluctuation of gene frequencies in small populations), gave Ashkenazi mitochondrial DNA its own distinct pattern over time, making it difficult to even trace its geographic origins.
The result is that the Ashkenazi population accumulated roughly 20 recessive hereditary disorders that are rarely found at comparable rates in other groups. “Recessive” means you need two copies of the variant, one from each parent, to develop the disease. Carriers who have just one copy are typically healthy, which allows these variants to persist silently across generations.
The Specific Diseases
The most well-known example is Tay-Sachs disease, a fatal neurological condition that destroys nerve cells in young children. About 1 in 27 Ashkenazi Jews in the United States carries the Tay-Sachs gene, compared to roughly 1 in 250 people in the general population. That tenfold difference is a direct fingerprint of the founder effect.
Gaucher disease type 1, which causes an abnormal buildup of fatty substances in organs like the spleen and liver, occurs in about 1 in 450 Ashkenazi births. A New York newborn screening program found that all confirmed cases of Gaucher type 1 during its study period were in babies of Ashkenazi descent. The prevalence in Ashkenazi populations can be as high as 139 per 100,000 people, compared to rates below 1 per 100,000 in most other populations.
Familial dysautonomia, a disorder affecting the sensory and autonomic nervous system, has a carrier frequency of about 1 in 32 among Ashkenazi Jews, with even higher rates (1 in 18) among those of Polish Ashkenazi descent specifically. This variation within the Ashkenazi population itself reflects the sub-bottlenecks that occurred as different communities migrated to different regions of eastern Europe.
Ashkenazi Jews also carry three specific variants in the BRCA1 and BRCA2 genes at elevated rates, increasing the risk of breast, ovarian, and prostate cancers. These aren’t rare recessive diseases in the traditional sense but rather dominant cancer-predisposition mutations that became common through the same founder dynamics.
Not Unique to Ashkenazi Jews
This pattern is not exclusive to one ethnic group. Any population that went through a severe bottleneck and then remained relatively isolated will accumulate its own set of elevated genetic risks. The Finnish population carries higher rates of certain diseases virtually unknown elsewhere. The Amish, descended from a small group of Swiss-German settlers, have their own cluster of rare conditions. French Canadians, who descend from a few thousand original colonists, show a similar pattern. Gene mapping efforts in all of these founder populations have identified numerous disease-causing mutations specific to each group.
What makes the Ashkenazi case particularly well studied is a combination of factors: the population is large (roughly 10.5 million today), the diseases are clinically severe and well characterized, and the community has actively participated in genetic research for decades.
Was There a Hidden Advantage?
One hypothesis that circulated for years suggested that carriers of certain Ashkenazi disease genes might have enjoyed a survival advantage, similar to how carrying one copy of the sickle cell gene protects against malaria. The most prominent version proposed that Tay-Sachs carriers had increased resistance to tuberculosis, which ravaged the crowded ghettos of medieval and early modern Europe.
The data hasn’t supported this. Studies comparing the causes of death among grandparents of Tay-Sachs carriers versus non-carriers found no difference in tuberculosis mortality. The current scientific consensus is that the high carrier frequencies are best explained by founder effects, genetic drift, and differential migration patterns, not by any protective benefit of carrying disease genes.
How Screening Has Changed the Picture
Community awareness of these genetic risks has led to some of the most successful genetic screening programs in history. In 1971, members of a Maryland synagogue, some of whom had lost children to Tay-Sachs, participated in pioneering carrier testing efforts. That early work eventually led to widespread screening.
Within Orthodox communities, a program called Dor Yeshorim, founded in 1983, allows young people to be tested confidentially before considering a match. If both partners carry the same recessive disease gene, they’re informed of the incompatibility. The program is credited with the near-total disappearance of Tay-Sachs disease from ultra-Orthodox communities.
Modern screening panels have expanded far beyond Tay-Sachs. Current Ashkenazi genetic testing panels cover up to 120 conditions, screening for 203 specific mutations across autosomal recessive, autosomal dominant, and X-linked disorders. The threshold for inclusion is a predicted frequency of at least 1 in 60,000 in the Ashkenazi population, which captures conditions so rare in other groups that they wouldn’t typically be screened for. These expanded panels mean that couples can now identify carrier risk for dozens of conditions before starting a family, turning a population’s historical vulnerability into one of the most proactive models of genetic prevention in medicine.